Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMichael H. TomassonMBMelissa L. Bates

Discussion

Loading...

Member takes

Overview

Single-cell RNA sequencing demonstrates altered gene expression in acute myeloid leukemia patients undergoing venetoclax-based therapy, suggesting potential treatment responses.

Key Points

  • Venetoclax-based therapy alters hematopoietic stem cell dynamics in acute myeloid leukemia patients, revealing distinct cellular profiles.
  • Differential gene expression analysis identified downregulation of pro-survival genes, suggesting enhanced apoptotic pathways.
  • Single-cell RNA sequencing provides insights into cellular diversity and treatment effects in the bone marrow during therapy.
  • These findings highlight potential biomarkers for response to venetoclax in the context of acute myeloid leukemia treatment.

Cite This Study

Tomasson et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce8https://doi.org/10.1182/blood-2025-1499
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomic insights into venetoclax response and resistance in secondary AML evolving from MDS2025
  2. 2Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025
  3. 3Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia2025 · 1 citations
  4. 4Factors affecting response and resistance to venetoclax in acute myeloid leukemia2025 · 6 citations
  5. 5Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia2025